



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Lacy

Phone: 650-351-4730

E-mail: investor@gbt.com

Stock Performance

GBT (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$50.71**

Change (%) 0.00 (0.00%)

Volume 0

52 Week Low \$30.15

Market Cap \$2,815,899,779

Rolling EPS -3.42

PE Ratio 0

Shares Outstanding 55,529,477

Data as of 02/19/19 4:00 p.m. ET



Recent Headlines & Events

02/19/19

[GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease](#)

02/05/19

[GBT Announces New Employment Inducement Grants](#)

01/29/19

[GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
02/14/19	<u>4</u>
02/14/19	<u>5</u>
02/14/19	<u>5</u>
02/14/19	<u>5</u>

Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.